Zobrazeno 1 - 10
of 723
pro vyhledávání: '"Nicolas JF"'
Publikováno v:
In Revue Française d'Allergologie November 2019 59(7):463-465
Autor:
Vanbervliet B., Vocanson M., Rozières A., Benetière J., Rouzaire P., Akdis CA., Nicolas JF., Hennino A.
Publikováno v:
J Allergy Clin Immunol.
Autor:
Girolomoni, G, Griffiths, CEM, Krueger, J, Nestle, FO, Nicolas, JF, Prinz, JC, Puig, L, Stahle, M, van de Kerkhof, PCM, Allez, M, Emery, P, Paul, C
Publikováno v:
JOURNAL OF DERMATOLOGICAL TREATMENT
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Psoriasis is an immune-mediated inflammatory disease (IMID) which may have a major impact on a patient's life, especially when the disease is moderate to severe. There is evidence that treatment of psoriasis during the first years is conservative and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::ac05fc7ab689e6bb50ca2cbfab4a488a
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14552
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14552
Autor:
Adamski, Z, Altomare, G, Aricò, M, Aste, N, Aubin, F, Augustin, M, Ayala, F, Bachelez, H, Baran, E, Barker, J, Belinchón, I, Berbis, P, Bernengo, Mg, Bessis, D, Beylot Barry, M, Bordas Orpinell, Fj, Burden, D, Bylaite, M, Cambazard, F, Carazo, S, Carrascosa, Jm, Carretero, G, Cerio, R, Chimenti, S, David, M, Duval Modeste, Ab, Eedy, D, Estebaranz, L, Filipe, P, Flytström, I, Fonseca, E, Gamanya, R, Ghislain, Pd, Giannetti, A, Girolomoni, G, Gospodinov, D, Griffiths, C, Grob, Jj, Guillet, G, Hernanz Hermosa, Jm, Hoffmann, M, Ioannidis, D, Jacobi, A, Jemec, G, Kadurina, M, Kaszuba, K, Katsambas, A, Kemeny, L, Kerkhof, P, Kragballe, K, Kuzmina, N, Lambert, K, Lázaro, P, Lotti, T, Luger, T, Matz, H, Modiano, P, Moessner, R, Moreno, D, Moreno Jímenez, Jc, Mørk, Nj, Mrowietz, U, Murphy, R, Nicolas, Jf, Nikkels, A, Oliveira, H, Ormerod, A, Ortonne, Jp, Parodi, A, Pasternack, R, Paul, C, Pec, J, PESERICO STECCHINI NEGRI DE SALVI, Andrea, Philipp, S, Piquet, L, Plantin, P, Puig, L, Reich, K, Reményik, E, Riedl, E, Röcken, M, Rustin, M, Saari, S, Saiag, P, Salmhofer, W, Schadendorf, D, Sebastian, M, Simaljakova, M, Simon, Jc, Spirén, A, Stalder, Jf, Stavrianeas, N, Sticherling, M, Ternowitz, T, Thaci, D, Thio, B, Uhlig, D, Valiukeviciene, S, Vanaclocha Sebastián, Fj, Wozel, G.
Publikováno v:
Paul, C, Puig, L, Kragballe, K, Luger, T, Lambert, J, Chimenti, S, Girolomoni, G, Nicolas, J-F, Rizova, E, Lavie, F, Mistry, S, Bergmans, P, Barker, J & Reich, K 2013, ' Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate : a randomized clinical trial (TRANSIT) ', British Journal of Dermatology . https://doi.org/10.1111/bjd.12646
BRITISH JOURNAL OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
BRITISH JOURNAL OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: limited data exist on transitioning patients with psoriasis from conventional systemic agents to biologics. Objectives: the TRANSIT study aimed to assess the efficacy and safety of two methotrexate-to-ustekinumab transition strategies. Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03c93721f9dab43d46bffd5dc0ea9646
https://pure.au.dk/portal/da/publications/transition-to-ustekinumab-in-patients-with-moderatetosevere-psoriasis-and-inadequate-response-to-methotrexate(13b2ea5a-7df1-4207-b3f8-29cec19f356e).html
https://pure.au.dk/portal/da/publications/transition-to-ustekinumab-in-patients-with-moderatetosevere-psoriasis-and-inadequate-response-to-methotrexate(13b2ea5a-7df1-4207-b3f8-29cec19f356e).html
Autor:
Adamski, Z, Altomare, G, Aricò, M, Aste, N, Aubin, F, Augustin, M, Ayala, F, Bachelez, H, Baran, E, Barker, J, Belinchón, I, Berbis, P, Bernengo, Mg, Bessis, D, Beylot Barry, M, Bordas Orpinell, Fj, Burden, D, Bylaite, M, Cambazard, F, Carazo, S, Carrascosa, Jm, Carretero, G, Cerio, R, Chimenti, S, David, M, Duval Modeste, Ab, Eedy, D, Estebaranz, L, Filipe, P, Flytström, I, Fonseca, E, Gamanya, R, Ghislain, Pd, Giannetti, A, Girolomoni, G, Gospodinov, D, Griffiths, C, Grob, Jj, Guillet, G, Hernanz Hermosa, Jm, Hoffmann, M, Ioannidis, D, Jacobi, A, Jemec, G, Kadurina, M, Kaszuba, K, Katsambas, A, Kemeny, L, Kerkhof, P, Kragballe, K, Kuzmina, N, Lambert, K, Lázaro, P, Lotti, T, Luger, T, Matz, H, Modiano, P, Moessner, R, Moreno, D, Moreno Jímenez, Jc, Mørk, Nj, Mrowietz, U, Murphy, R, Nicolas, Jf, Nikkels, A, Oliveira, H, Ormerod, A, Ortonne, Jp, Parodi, A, Pasternack, R, Paul, C, Pec, J, PESERICO STECCHINI NEGRI DE SALVI, Andrea, Philipp, S, Piquet, L, Plantin, P, Puig, L, Reich, K, Reményik, E, Riedl, E, Röcken, M, Rustin, M, Saari, S, Saiag, P, Salmhofer, W, Schadendorf, D, Sebastian, M, Simaljakova, M, Simon, Jc, Spirén, A, Stalder, Jf, Stavrianeas, N, Sticherling, M, Ternowitz, T, Thaci, D, Thio, B, Uhlig, D, Valiukeviciene, S, Vanaclocha Sebastián, Fj, Wozel, G.
Publikováno v:
Reich, K, Puig, L, Paul, C, Kragballe, K, Luger, T, Lambert, J, Chimenti, S, Girolomoni, G, Nicolas, J-F, Rizova, E, Brunori, M, Mistry, S, Bergmans, P & Barker, J 2013, ' One year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment : the TRANSIT randomized trial in moderate-to-severe plaque psoriasis ', British Journal of Dermatology . https://doi.org/10.1111/bjd.12643
BRITISH JOURNAL OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
BRITISH JOURNAL OF DERMATOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: There are limited long-term, ‘real-world’ data on ustekinumab, or the effect of dose adjustment in suboptimal responders. Objectives: We describe 52-week data from TRANSIT, which initiated ustekinumab by licensed regimen and investiga